| Code | CSB-RA004847MB1HU |
| Size | US$9799 |
| Order now | |
| Have Questions? | Leave a Message or Start an on-line Chat |
This recombinant monoclonal antibody is designed as a research-grade biosimilar to the reference antibody described in US20220060312A1, targeting CCR8 (C-C chemokine receptor type 8). CCR8 is a G protein-coupled receptor predominantly expressed on regulatory T cells (Tregs) and certain T helper cell subsets, where it mediates chemotactic responses to CCL1 and CCL18. This receptor plays a critical role in immune regulation and has emerged as a significant target in immuno-oncology research, as tumor-infiltrating Tregs often exhibit high CCR8 expression, contributing to immunosuppressive tumor microenvironments. CCR8 is implicated in various cancers including colorectal, breast, and non-small cell lung cancer, as well as in inflammatory and allergic diseases.
The reference antibody represents a therapeutic candidate developed for selective depletion of CCR8-positive Tregs to enhance anti-tumor immunity. This biosimilar provides researchers with a valuable tool for investigating CCR8 biology, Treg function, and immune checkpoint mechanisms. It supports studies examining tumor immunology, cancer immunotherapy development, and immune cell trafficking in disease contexts.
There are currently no reviews for this product.